Allakos Inc

NASDAQ:ALLK  
6.84
-0.34 (-4.74%)
Products

Allakos Announces Expansion Of Lirentelimab Development Into Atopic Dermatitis, Chronic Spontaneous Urticaria And Asthma

Published: 11/30/2021 12:58 GMT
Allakos Inc (ALLK) - Allakos Announces Expansion of Lirentelimab Development Into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma.
Allakos Inc - Phase 2 Atopic Dermatitis Trial of Subcutaneous Lirentelimab Initiated.
Allakos Inc - Phase 2/3 Chronic Spontaneous Urticaria Trial of Subcutaneous Lirentelimab to Begin in Mid 2022.
Allakos Inc - Phase 2 Asthma Trial of Subcutaneous Lirentelimab to Begin in Q4 2022.